cas 1289942-66-0|| where to buy 2-((3-Fluoro-4-(methylcarbamoyl)phenyl)amino)-2-methylpropanoic acid

Nombre del producto:2-((3-Fluoro-4-(methylcarbamoyl)phenyl)amino)-2-methylpropanoic acid

IUPAC Name:2-{[3-fluoro-4-(methylcarbamoyl)phenyl]amino}-2-methylpropanoic acid

Unidad de embalaje	Stock disponible	Precio($)
CM248707-500g	in stock	ŁĨĨ
CM248707-1000g	in stock	ǎřř

Sólo para uso en I+D..

Formulario de consulta

Nombre químico

Número CAS

Cantidad*

Especificaciones requeridas*
(% de ensayo, grado de material, etc.)

Nombre de contacto*

Correo electrónico de contacto*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 1289942-66-0 regularly via the above email.

Notas adicionales

Verification code*

refresh

: Núm. De CAS :1289942-66-0; Fórmula molecular:C12H15FN2O3; Punto de fusión:-; Código de sonrisas:CC(C)(NC1=CC=C(C(NC)=O)C(F)=C1)C(O)=O; Densidad:

: Número de catálogo:CM248707; Peso molecular:254.26; Punto de ebullición:455.1°C at 760 mmHg; Nº Mdl:MFCD22581651; Almacenamiento:Store at 2-8°C.

: Amino Acids and Peptides; Amino acids are organic compounds containing a basic amino group and an acidic carboxyl group. Because amino acids contain both amino and carboxyl groups, they can be polymerized in an end-to-end manner, removing a molecule of water to form a covalent amide bond or peptide bond. Many amino acids are linked together end to end to form a polypeptide. Amino acids and peptides are important components in the fields of medicine and life sciences.; amino acids wholesale; if you are finding amino acids wholesaler in china, we will be your best choose! We have our own factory, so we can give you a cheap price!

: Enzalutamide; Aug. 23, 2023, FDA grants priority review for XTANDI(enzalutamide) in non-metastatic castration-sensitive prostate cancer with high-risk biochemical recurrence.
XTANDI (enzalutamide) is an androgen receptor signaling inhibitor. Androgen receptor inhibitors interfere with the connection between androgens and androgen receptors. This can help slow cancer cell growth.XTANDI is currently approved for one or more of these indications in more than 100 countries, including in the U.S., European Union and Japan. Over one million patients have been treated with XTANDI globally.